Trial Profile
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Afamelanotide (Primary)
- Indications Variegate-porphyria
- Focus Proof of concept; Therapeutic Use
- Acronyms Phase IIa VP Study
- Sponsors Clinuvel Pharmaceuticals
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 10 Oct 2023 According to a Clinuvel Pharmaceuticals media release, outcomes from this study is expected in next year.
- 10 Jul 2023 Status changed from recruiting to active, no longer recruiting.